The HPV vaccine is one of the most effective vaccines ever developed. In countries with high vaccination coverage, cervical cancer rates have dropped by 34% to 87%, with the strongest results seen in people vaccinated before age 15. The vaccine also prevents genital warts, anal cancer, and several other HPV-related conditions with similarly high effectiveness.
How Well It Prevents Cervical Cancer
The most striking numbers come from real-world data now spanning more than a decade. In England, women vaccinated between ages 12 and 13 saw an 87% reduction in cervical cancer compared to unvaccinated groups. In Denmark, the reduction was 86% for girls vaccinated at 16 or younger, and 68% for those vaccinated between 17 and 19.
The vaccine works by preventing the infections that lead to cancer, so it also dramatically cuts the precancerous changes that doctors find during Pap smears and cervical screenings. Among people who received the full vaccine series before being exposed to HPV, the current nine-strain vaccine prevented roughly 97% of high-grade precancerous lesions caused by the strains it targets. Even in broader populations that included people who may have already been exposed to some HPV strains, effectiveness against high-grade disease was around 81%.
Protection Beyond Cervical Cancer
HPV causes cancers in several parts of the body, not just the cervix, and the vaccine works against those too. In clinical trials of men aged 16 to 26, the vaccine prevented 90% of external genital lesions and 86% of persistent infections with the targeted HPV types. Among men who have sex with men, it prevented 75% of high-grade anal precancerous lesions and 95% of anal HPV infections with vaccine-targeted strains.
For genital warts specifically, the population-level results have been dramatic. Among teen girls in the United States, infections with the HPV types responsible for most cancers and genital warts have dropped 88% since widespread vaccination began. Among young adult women, that figure is 81%.
Age at Vaccination Makes a Big Difference
The vaccine works best when given before a person has any sexual contact, because it prevents infection rather than treating an existing one. The data consistently shows a steep drop in effectiveness the later someone gets vaccinated. People who received their first dose at age 18 or younger had 75% vaccine effectiveness against cervical disease. Those vaccinated after 18 had only 43% effectiveness, and that result wasn’t statistically significant, meaning it could have been due to chance.
This gap explains why health authorities recommend vaccination starting at age 9 to 12. At that age, the immune response is strong and the chance of prior HPV exposure is essentially zero. It also explains why the most impressive population-level results come from countries that vaccinate early in adolescence.
One Dose vs. Two Doses
For years, the standard schedule was three doses, later reduced to two for people starting before age 15. Recent evidence has pushed that number even lower. A major NIH-supported trial found that a single dose of HPV vaccine provided protection statistically comparable to two doses, with both regimens reaching at least 97% effectiveness against persistent infections with the two most dangerous HPV strains (types 16 and 18). The World Health Organization now endorses a single-dose option, which has made vaccination programs far more practical in countries with limited healthcare infrastructure.
People who start the series at age 15 or older are still recommended to receive multiple doses, because the immune response at older ages benefits from the additional boost.
How Long Protection Lasts
The current nine-strain vaccine has been tracked for about 10 years since its introduction, and protection has held steady through that entire follow-up period. In a long-term study of boys and girls vaccinated between ages 9 and 15, there were zero cases of high-grade precancerous lesions or genital warts related to the targeted HPV types across a median of 10 years of monitoring. Antibody levels remain detectable throughout, and no booster dose is currently recommended. Earlier versions of the vaccine have even longer track records with similarly durable results.
Herd Protection for Unvaccinated People
One of the more notable effects of widespread HPV vaccination is that it protects people who never received the vaccine. When enough people in a community are vaccinated, the virus has fewer hosts to circulate through, so even unvaccinated individuals benefit. Among sexually active women aged 14 to 26 in the United States, HPV infections with vaccine-targeted types dropped 89% in vaccinated women and 34% in unvaccinated women compared to pre-vaccine levels. This herd effect grows stronger as vaccination coverage increases.
As of 2024, about 78% of U.S. adolescents aged 13 to 17 had received at least one dose of the HPV vaccine, though only 63% were fully up to date with the recommended series.
Side Effects and Safety
The HPV vaccine has one of the most thoroughly studied safety profiles of any vaccine. More than 80 million doses of the earlier formulation alone were distributed in the U.S. between 2006 and 2017, providing a massive dataset. The most common side effects are soreness at the injection site, mild fever, headache, fatigue, and nausea. These are typical of most vaccines and generally resolve within a day or two.
Serious adverse event reports are rare. For the current nine-strain vaccine, about 97% of all reports to the federal vaccine safety monitoring system were classified as non-serious. The roughly 3% classified as serious included events like high fevers or allergic reactions, and the classification of “serious” in this system casts a wide net, including any event that results in a medical visit regardless of whether the vaccine caused it. Large-scale safety reviews have not identified patterns of serious harm linked to HPV vaccination.